IMPEDIMED LIMITED — Capital/Financing Update 2009

Mar 11, 2009

12[th] March 2009

==> picture [110 x 104] intentionally omitted <==

----- Start of picture text ----- ASX : IPD----- End of picture text -----

ASX RELEASE - ESCROW RELEASE

ImpediMed Limited is required to advise the market 10 working days prior to the release of any shares from escrow. The company wishes to give that advice for a block of 14,370,317 ordinary shares which were originally subject to voluntary escrow until 24[th] October 2008, and for which a holding lock has remained in place.

The company proposes to release the shares from escrow and remove the holding lock on 30[th] March 2009.

With respect to the block of shares:

• It constitutes 14,370,317 listed ordinary shares which were originally subject to voluntary escrow until 24[th] October 2008.

• There are seven holders:

  • 1,212,025 shares Greg Brown

    • A parcel held directly by the CEO and director Greg Brown

  • 97,336 shares Parma Corporation

    • A company associated with the Chairman Mel Bridges

  • 6,395,783 shares Starfish Technology Fund

    • A venture investor in which director Dr Michael Panaccio is a principal

o 4,832,081 shares Versant Ventures (via 2 investing entities)

• A US based venture investor

o 916,546 shares Statewide Superannuation Pty Ltd  An institutional investor

• 916,546 shares Westscheme Pty Ltd  An institutional investor

Those holders or controllers who comprise members of the board have confirmed they have no near term plans to dispose of any of the shares on market as a result of their release from escrow. In fact Mr Bridges and Mr Brown have joined other directors in adding to their holdings during the trading window open under the company’s share trading policy following release of half year results to 31[st] December 2008.

The table below summarises ImpediMed’s securities on issue following the release from escrow and the ESOP share and option grant advised earlier today.

==> picture [469 x 277] intentionally omitted <==

Phil Auckland CFO & Company Secretary

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.